공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

인터류킨 2 수용체 서브유닛 알파(TAC 항원, p55, CD25, IL2RA) : 파이프라인 리뷰

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 361640
페이지 정보 영문 74 Pages
가격
US $ 3,500 ₩ 3,887,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,774,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,661,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인터류킨 2 수용체 서브유닛 알파(TAC 항원, p55, CD25, IL2RA) : 파이프라인 리뷰 Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 74 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 각국에서의 인터류킨 2 수용체 서브유닛 알파(TAC 항원 또는 p55 또는 CD25 또는 IL2RA) 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험의 각 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

인터류킨 2 수용체 서브유닛 알파(TAC 항원/p55/CD25/IL2RA) 개요

치료제 개발

  • 인터류킨 2 수용체 서브유닛 알파(TAC 항원/p55/CD25/IL2RA)의 파이프라인 제품 : 개요

인터류킨 2 수용체 서브유닛 알파(TAC 항원/p55/CD25/IL2RA) : 각 기업에서 개발중인 치료제

  • 임상시험 단계별
  • 치료 영역별
  • 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

각 기업에서 개발중인 치료제

치료제 평가

  • 단일요법 치료제/병용 치료제의 경우
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • AbbVie Inc.
  • Alkermes Plc
  • APT Therapeutics, Inc.
  • Mabtech Limited
  • Philogen S.p.A.

약제 개요

  • APT-602
    • 제품 개요
    • 작용기서
    • 연구개발(R&D)의 진전 상황
  • 바실릭시맙
  • 바실릭시맙 바이오베터
  • 다클리주맙
  • Darleukin
  • RDB-1450

개발이 휴지 상태인 제품

주목할 만한 최신 동향·프레스 릴리스(총 15건)

부록

도표

KSA 16.08.01

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Alkermes Plc, H2 2019
  • Pipeline by Anaveon AG, H2 2019
  • Pipeline by APT Therapeutics Inc, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Courier Therapeutics Inc, H2 2019
  • Pipeline by Mabtech Ltd, H2 2019
  • Pipeline by Medicenna Therapeutics Corp, H2 2019
  • Pipeline by Nektar Therapeutics, H2 2019
  • Pipeline by Philogen SpA, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 5 respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Plaque Psoriasis (Psoriasis Vulgaris), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Diabetic Nephropathy, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Inflammation, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Relapsed Acute Myeloid Leukemia, Skin Cancer, Soft Tissue Sarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).

The latest report Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
  • Alkermes Plc
  • Anaveon AG
  • APT Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Courier Therapeutics Inc
  • Mabtech Ltd
  • Medicenna Therapeutics Corp
  • Nektar Therapeutics
  • Philogen SpA
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
  • ALKS-4230 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APT-602 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • basiliximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • basiliximab biobetter - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CC-92252 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • daclizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • darleukin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • daromun - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDNA-209 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NARA-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NKTR-358 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teleukin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
  • Nov 08, 2019: Alkermes announces new data from ALKS 4230 clinical development program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
  • Nov 04, 2019: Alkermes to present data from ALKS 4230 clinical development program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
  • Oct 21, 2019: Alkermes announces clinical collaboration with Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
  • Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis
  • Jun 13, 2019: First-in-Human data presented from Phase 1a Study of NKTR-358, a novel t regulatory cell stimullator, at Annual European Congress of Rheumatology
  • Jun 12, 2019: Alkermes advances ALKS 4230 into monotherapy expansion Phase of ARTISTRY-1 in patients with renal cell carcinoma or melanoma
  • Jun 11, 2019: Nektar Therapeutics to host webcast conference call with immunology expert for analysts & investors during 2019 European Congress of Rheumatology (EULAR 2019)
  • Feb 26, 2019: Alkermes initiates clinical study of ALKS 4230 administered subcutaneously in patients with advanced solid tumors
  • Nov 06, 2018: Alkermes presents new data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
  • Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours
  • Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
  • May 18, 2018: EMA review of Zinbryta confirms medicine's risks outweigh its benefits
  • May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
  • Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q